Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?
Shyu
Kou-Gi
KG
D000804:Angiotensin II / Q000502:physiology / Q000633:toxicity; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000818:Animals; D006332:Cardiomegaly / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D016207:Cytokines / Q000378:metabolism; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000502:physiology; D005347:Fibroblasts / Q000187:drug effects / Q000502:physiology*; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D007545:Isoproterenol / Q000633:toxicity; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology; D044403:Receptor, Serotonin, 5-HT2B / Q000502:physiology*; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
D047228:Angiotensin II Type 1 Receptor Blockers; D016207:Cytokines; C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; C587885:Hbegf protein, rat; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D061965:Matrix Metalloproteinase Inhibitors; D044140:Receptor, Angiotensin, Type 1; D044403:Receptor, Serotonin, 5-HT2B; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; D000804:Angiotensin II; D066246:ErbB Receptors; D020782:Matrix Metalloproteinases; D007545:Isoproterenol